ArticleScience translational medicine2009
Traversing the valley of death: a guide to assessing prospects for translational success.
Article in Science translational medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessing excellence in translational cancer research: a consensus based framework.Journal of translational medicine · 2013Pooled it
- Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans.Clinical and translational science · 2017Trial
- Smart biomaterials for skeletal aging repair and regeneration.Bone research · 2026Review
- Integrin Targeting Therapies in Pulmonary Arterial Hypertension: A Roadmap for Traversing the Translational Valley of Death?Circulation · 2025Article
- Navigating the challenges of initiating pediatric device trials - a case study.Journal of clinical and translational science · 2024Article
- Exploring regulatory flexibility to create novel incentives to optimize drug discovery.Frontiers in medicine · 2024Review
- Customized Surface Design to Increase Throughput of Ambient Ionization Mass Spectrometry Lipidomics.Journal of the American Society for Mass Spectrometry · 2023Article
- Who counts as an inventor? Seniority and gender in 430,000 biomedical inventor-researcher teams.Nature biotechnology · 2023Article
- Translational research: from basic research to regional biomedical entrepreneurship.Small business economics · 2023Article
- Comprehensive analysis of 2.4 million patent-to-research citations maps the biomedical innovation and translation landscape.Nature biotechnology · 2021Article
- On the road to smart biomaterials for bone research: definitions, concepts, advances, and outlook.Bone research · 2021Review
- "Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call to Action".Human vaccines & immunotherapeutics · 2019Review
- An experimental toolbox for characterization of mammalian collagen type I in biological specimens.Nature protocols · 2018Article
- Biomarker definitions and their applications.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- Commentary: how will interventional oncology navigate the "valleys of death" for new medical devices?The British journal of radiology · 2018Article
- Getting Digital Assets from Public-Private Partnership Research Projects through "The Valley of Death," and Making Them Sustainable.Frontiers in medicine · 2018Review
- Tissue chips - innovative tools for drug development and disease modeling.Lab on a chip · 2017Review
- The Use of Community Engaged Research Principles to Improve Health: Community Academic Partnerships for Research.Puerto Rico health sciences journal · 2017Article
- Warning About Shortcuts in Drug Development.Journal of the American Heart Association · 2017Article
- Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest.Clinical and translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
On the basis of our experience in drug and device development, we have identified six broad categories of issues that profoundly affect the probability for successful translation of basic scientific discoveries into effective therapies. Within each category, we propose a series of questions that form the beginnings of a self-guided global risk assessment tool. Although this preliminary tool will require validation and adjustment, we offer it to stimulate a discussion about more rigorous methods for selecting and conducting translational projects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.